Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 127 in Healthy Participants and Participants With Type 2 Diabetes Mellitus
NCT07590193Phase 1Recruiting
- Sponsor
- Amgen
- Start
- Jun 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AMG 127 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Amgen. Primary endpoints: Number of Treatment-Emergent Adverse Events up to 87 days, Number of Serious Adverse Events up to 115 days and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
AMG 127
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07590193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07590193.